A Multicenter Phase II Trial with Irinotecan plus Oxaliplatin as First-Line Treatment for Inoperable/Metastatic Cancer of the Biliary Tract

Publisher： Karger

E-ISSN： 1423-0232|78|5-6|356-360

ISSN： 0030-2414

Source： Oncology, Vol.78, Iss.5-6, 2010-08, pp. : 356-360

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oxaliplatin, Irinotecan and Capecitabine (OCX) for First-Line Treatment of Advanced/Metastatic Colorectal Cancer: A Phase I Trial (SAKK 41/03)

By  

Oncology Research and Treatment, Vol. 33, Iss. 6, 2010-05 ,pp. : 295-299

Karger

Access to resources Recommend Favorite

Oxaliplatin as First-Line Treatment in Inoperable Biliary Tract Carcinoma

By  

Oncology, Vol. 70, Iss. 4, 2006-10 ,pp. : 280-284

Karger

Access to resources Recommend Favorite

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

By  

Oncology, Vol. 73, Iss. 1-2, 2008-03 ,pp. : 9-20

Karger

Access to resources Recommend Favorite

Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI Regimen) as First Line Treatment for Elderly Patients with Metastatic Colorectal Cancer: A Phase II Trial

By  

Oncology, Vol. 69, Iss. 5, 2005-12 ,pp. : 384-390

Karger

Access to resources Recommend Favorite

Weekly Docetaxel and Gemcitabine as First-Line Treatment for Metastatic Breast Cancer: Results of a Multicenter Phase II Study

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 438-445

Karger

Access to resources Recommend Favorite